In a randomized clinical trial repurposing imatinib, a tyrosine kinase inhibitor of the KIT proto-oncogene receptor tyrosine kinase, for severe asthma, imatinib use improved forced expiratory volume in 1 s (FEV1) compared to placebo treatment [4]. This evidence concerns the gene KIT and asthma.